BenevolentAI joins the World Economic Forum’s Global Innovators Community

· The invitation only group represents a collective of companies at the forefront of ethical technological and business model innovation working on solutions to our world’s most significant challenge

· BenevolentAI will be part of the global effort to ethically deploy the use of AI to create a more sustainable, inclusive and resilient world

London, 21 April 2022, BenevolentAI, a leading clinical-stage artificial intelligence (AI) enabled drug discovery company, today announced that it has joined the World Economic Forum’s (WEF) Global Innovators Community, to help advance and scale governance and policies that support the responsible deployment of AI. BenevolentAI will join the world’s most promising start-ups and scale-ups in a common effort to engage with public and private sector leaders and contribute to developing new solutions to pressing global challenges and build future resilience. 

Joanna Shields, CEO at BenevolentAI and Co-Chair of the Global Partnership on AI (GPAI), commented; “Billions of dollars are invested in drug development each year, yet persistently high failure rates and low efficacy are leaving too many patients without hope for a cure. It is critical we reinvent our approach to deliver on this pressing global health need. Our mission at BenevolentAI is to bring about a transformation in drug discovery by harnessing AI to better understand disease biology and ultimately improve patient outcomes. We are proud to collaborate with the World Economic Forum to help ensure AI is ethically deployed for the benefit of patients worldwide.” 

As part of the Global Innovators Community, BenevolentAI will participate in the WEF’s Annual Meeting, taking place in Davos-Klosters, Switzerland, from Sunday the 22nd to Thursday the 26th of May, where CEO Joanna Shields will join two panels on ‘Unlocking the Power of Digital Health’ and on the ‘Use of Responsible AI for Societal Gains’. Topics on the agenda will also include the pandemic recovery and harnessing the technologies of the Fourth Industrial Revolution. Being the first global in-person leadership event since the start of the pandemic, the Annual Meeting 2022 will be a crucial opportunity for members to reconnect and will be the starting point for a new era of global responsibility and cooperation. 

“The World Economic Forum is happy to have BenevolentAI join our Global Innovators community,” said Kay Firth-Butterfield, Head of Artificial Intelligence & Machine learning at the World Economic Forum. “We are delighted to engage BenevolentAI in our platform's work to champion and demonstrate how responsible and trustworthy AI can help deliver on societal goals in critical areas like healthcare.”

About BenevolentAI

BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

About the World Economic Forum 

The World Economic Forum is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas. It was established in 1971 as a not-for-profit foundation and is headquartered in Geneva, Switzerland. It is independent, impartial and not tied to any special interests. The Forum strives in all its efforts to demonstrate entrepreneurship in the global public interest while upholding the highest standards of governance. Moral and intellectual integrity is at the heart of everything it does.

Media Contacts

Rajin Kang - VP Communications

Tricia Persad-Bevil – JPA Health

More Posts

You Might Also Like

BenevolentAI announces participation in upcoming investor conferences
BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.
Jun 10, 2022
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022